Interleukin-3 receptor subunit alpha is a protein in humans that is encoded by IL3RA gene. This is a receptor for interleukin-3.
The following IL3RA reagents supplied by CUSABIO are manufactured under a strict quality control system. Multiple applications have been validated and solid technical support is offered.
IL3RA Antibodies for Homo sapiens (Human)
|Code||Product Name||Species Reactivity||Application|
IL3RA Proteins for Homo sapiens (Human)
|CSB-CF011658HU||in vitro E.coli expression system|
In Vivo Biotinylation in E.coli
IL3RA Proteins for Mus musculus (Mouse)
|CSB-CF011658MO||in vitro E.coli expression system|
In Vivo Biotinylation in E.coli
Interleukin-3 receptor alpha chain (IL3RA), also known as CD123 (Cluster of Differentiation 123), is one of the two subunits of heterodimeric human IL-3R . The IL-3 receptor was first described on murine bone marrow cells. IL3RA belongs to a member of the cytokine receptor superfamily  but is more closely related to the GM-CSF receptor alpha chain (GM-CSFRA) and IL-5RA chains . The expression of both IL3RA and beta subunit IL3RB, the other IL-3R chain, is necessary for triggering signalling and cellular proliferation in response to IL-3 . Human IL-3 induces heterodimerization of IL-3R alpha and beta subunit IL3RB and that disulfide linkage of these chains is involved in receptor activation but not high-affinity binding . Interaction between the human IL-3R and IL-3 triggers a variety of cellular signals leading to the preservation of cell viability, proliferation, and differentiation of hemopoietic cells against apoptosis . Yao Tong et al. revealed the IL3RA is targeted for ubiquitination and degradation by the E3 ligase RNFT2 (RING finger transmembrane-domain containing protein 2, also TMEM118) and identifyied IL3RA Lys357 as a critical residue regulating IL3RA stability . In vitro, IL3 promotes RNFT2-dependent IL3RA proteasomal degradation, an effect mitigated by LPS-priming. No mutations of the IL3RA gene have been reported in hematological and non hematological human malignancies . Increased IL3RA expression has been reported in about 45% of patients with acute myeloid leukemia  and in 40% of patients with acute B lymphoid leukemia.
 Kitamura T., N. Sato, et al. Expression cloningof the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors [J]. Cell 1991, 66:1165-1174.
 Bazan, J. F. Structural design and molecular evolution of a cytokinereceptor superfamily [J]. Proc. Natl. Acad. Sci. USA 1990, 87:6934-6938.
 Goodall G. J., C. J. Bagley, et al. A model for the interaction of the GM-CSF, IL-3 and IL-5 receptors with their ligands [J]. Growth Factors 1993, 8:87-97.
 Kitamura T., and A. Miyajima. Functional reconstitution of the human interleukin-3 receptor [J]. Blood 1992, 80:84-90.
 F C Stomski, Q Sun, et al. Human interleukin-3 (IL-3) induces disulfide-linked IL-3 receptor alpha- and beta-chain heterodimerization, which is required for receptor activation but not high-affinity binding [J]. MOLECULAR AND CELLULAR BIOLOGY, June 1996, 3035-3046.
 Clark, S. C., et al. The human hematopoietic colony-stimulating factors [J]. Science 1987, 236:1229-1237.
 Metcalf D. The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells [J]. Nature (London) 1989, 339:27-30.
 Yao Tong, Travis B. Lear, et al. The RNFT2/IL3Ra axis regulates IL3 signaling and innate immunity [J]. JCI Insight. 2020;5(3):e133652.
 Muñoz L, Nomdedéu JF, et al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica. 2001 ; 86 (12) : 1261-1269.
 Riccioni R, Rossini A, et al. Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain [J]. Leukemia & lymphoma. 2004 ; 45 (8) : 1511-1517.